CCCS invites feedback over merger concerns on PAH deals
Response will help watchdog assess if planned consolidation of two clinical laboratories will reduce competition
Add BT as a preferred source
Fiona Lam
Singapore
THE Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in its planned merger of two private clinical laboratories.
PAH, a unit of private equity giant TPG Capital Asia, intends to integrate the businesses of the two labs - Innovative Diagnostics and Quest Laboratories - after acquiring them last year.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Gojek founder Nadiem Makarim faces 18-year jail demand in Indonesia laptop graft trial
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
Beyond corporate life: Why some Singaporeans choose portfolio careers
